

# Notification of transactions

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	Øystein Rekdal	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	CEO in Lytix Biopharma	
b)	Initial notification/Amendment	Initial notification	
<b>3</b>	<b>Details of issuer</b>		
a)	Name	Lytix Biopharma AS	
b)	LEI	549300NXMIMRSBCDZO71	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument Identification code	<i>Ordinary shares</i> <i>ISIN NO0010405780</i>	
b)	Nature of the transaction	<i>Purchase of ordinary shares</i>	
c)	Price(s) and volume(s)	<b>Price(s)</b> NOK 7.7274	<b>Volume(s)</b> 13,000
d)	Aggregated information — Aggregated volume — Price	— 13,000 ordinary shares — NOK 7,7274	
e)	Date of the transaction	2022.08.26	
f)	Place of the transaction	MERK-Euronext growth Oslo	